Results 221 to 230 of about 75,992 (272)

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. [PDF]

J Immunother Cancer
Bryant JM, Sandoval M, Putney R, Trivedi P, Katende EN, Fink A, Naqvi SM, Kim Y, Yin V, Zhang J, Park JY, Serna A, Lam N, Pow-Sang J, Poch M, Li R, Manley BJ, Naghavi A, Torres-Roca J, Grass GD, Kim S, Latifi K, Hunt D, Johnstone P, Dhillon J, Rodriguez PC, Jain R, Fernandez DC, Yamoah K.   +28 more
europepmc   +1 more source

Detection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite‐unstable gastrointestinal cancers: A pilot study

International Journal of Cancer, Volume 158, Issue 12, Page 3312-3323, 15 June 2026.
What's new? A substantial proportion of patients with microsatellite‐unstable gastrointestinal adenocarcinomas do not benefit from immunotherapy. This study demonstrates that microsatellite instability can be reliably detected in plasma‐derived extracellular vesicle DNA from patients with microsatellite‐unstable gastrointestinal cancers.
Aysel Ahadova, Lena Bohaumilitzky, Thomas Walle, Joscha A. Kraske, Mirjam Tariverdian, Ulrike Ganserer‐Schmitt, Ingrid Hausser‐Siller, Vera Fuchs, Nina Nelius, Gizem Mehtap Erisen, Johannes Gebert, Albrecht Stenzinger, Dirk Jäger, Magnus von Knebel Doeberitz, Georg Martin Haag, Elena Busch, Matthias Kloor   +16 more
wiley   +1 more source

Long-term complete remission of metastatic combined hepatocellular-cholangiocarcinoma with nivolumab following failure of targeted therapies: a case report. [PDF]

Front Oncol
Hong YM.
europepmc   +1 more source

Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report. [PDF]

Am J Case Rep
Vromans AM, Constantinou M.
europepmc   +1 more source

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions. [PDF]

Cancers (Basel)
Pravisano F, Costa J, Marchi L, Pascoletti G, Poletto E, Del Vecchio M, Spagnoletti A, Cimminiello C, Papadopoulos N, Pigozzo J, Piccin L, Roccuzzo G, Fava P, Puglisi F, Aprile G, Minisini AM.   +15 more
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy. [PDF]

J Gastric Cancer
Kim HD, Lee H, Lee SY, Lee Y, Hyung J, Moon M, Shin J, Park YS, Ryu MH.   +8 more
europepmc   +1 more source